Komodo Health: A Qualified Entity

Use of Imaging Studies for Low Back Pain (LBP)
(Measurement Year 2021)

Komodo Health has adopted a new measure that looks at the use of diagnostic imaging following a low back pain diagnosis. Analyses were conducted to measure rate differences by age, sex, race, ethnicity, and insurance group.

Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2020)

Reported rates continue to suggest that there remain a substantial number of patients who are at-risk for hyperglycemia and diabetes mellitus by virtue of their exposure to atypical antipsychotics, but are not being screened. The data suggest that the COVID pandemic may have created additional risk related to delay in identification or intervention for hyperglycemia or medication-induced diabetes.

Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2019) 

A new report by Komodo Health found overall diabetes screening rates have fluctuated for several years, suggesting that there may be a substantial number of patients who are at-risk for hyperglycemia and diabetes mellitus, by virtue of their exposure to atypical antipsychotics, who are not being screened.

Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (Measurement Year 2019)

A new analysis found that although three-year DMARD dispense rates have increased overall, rates for Medicaid Managed Care and the Medicare-Medicaid Dual groups trended downward (as compared to 2018).

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2018)

Komodo Health conducted an analysis on whether patients with schizophrenia or bipolar disorder who were prescribed an antipsychotic medication had a diabetes screening during the measurement year.

Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (Measurement Year 2018)

Komodo Health conducted an analysis of patients who were diagnosed with rheumatoid arthritis and received at least one Disease Modifying Anti-Rheumatic Drug (DMARD) during the measurement year.

Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (Measurement Year 2017)

An analysis conducted by Komodo Health finds that a patient’s insurance type and the location of where the patient lives play a major role in prescription dispensing patterns, with only 54% of eligible patients with RA receiving potentially Disease Modifying Anti-Rheumatic Drugs (DMARDs).

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2017)

According to an analysis conducted by Komodo Health, many patients who are prescribed medications that can disrupt normal serum glucose control do not receive annual screening for diabetes and other metabolic disorders.